Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637437 | 0.87 | ADORA2B (0.58) | ADORA2BACACBACACA | |
| SCHEMBL16644058 | 0.86 | ADORA2B (0.70) | ADORA2BADORA2AADORA1ADORA3POLB | |
| SCHEMBL16644036 | 0.85 | ADORA2B (0.46) | ADORA2BADORA2AADORA1POLBACACB | |
| SCHEMBL16637770 | 0.85 | ADORA2B (0.58) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL16637504 | 0.84 | ADORA2B (0.46) | ADORA2BADORA2AADORA1ACACBACACA | |
| SCHEMBL16637826 | 0.84 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ACACBACACA | |
| SCHEMBL16637359 | 0.83 | ADORA2B (0.55) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL16642316 | 0.83 | ADORA2B (0.74) | ADORA2BADORA2AADORA1ADORA3ACACB | |
| SCHEMBL16637406 | 0.80 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ACACBACACA | |
| SCHEMBL16644047 | 0.80 | ADORA2B (0.61) | ADORA2BADORA2AADORA1ADORA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-3055313-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885ADORA2A 167/4885ADORA1 451/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | ADORA2B 487/4885ADORA2A 167/4885ADORA1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.